In 2024, AstraZeneca completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
AstraZeneca has also provided a category-level breakdown for 12 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore AstraZeneca’s data sources below and access millions more through our Disclosure Search.
In 2024, the total operational greenhouse gas (GHG) emissions of AstraZeneca amounted to 342,412 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of AstraZeneca decreased by 5.99%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a
In 2024, the total Scope 1 emissions of AstraZeneca were 125,386 metric tons of CO₂ equivalent (tCO₂e). a
Compared to the previous year (2023), AstraZeneca's Scope 1 emissions decreased by 30.69%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a
In 2024, AstraZeneca reported Scope 2 greenhouse gas (GHG) emissions of 14,210 tCO₂e using the market-based method and 217,026 tCO₂e using the location-based method. a
Compared to the previous year (2023), AstraZeneca's Scope 2 emissions (Location-Based) rose by 18.38% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a
In 2024, AstraZeneca reported its Scope 2 emissions using the market-based method and using the location-based method. a
In 2024, AstraZeneca reported 5,897,822 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2024 disclosure of AstraZeneca includes a breakdown across 12 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
In 2024, AstraZeneca reported total Scope 3 emissions of 5,897,822 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 76.34% of these emissions originated from upstream activities such as purchased goods and capital goods, while 23.66% came from downstream activities like product use, distribution, and end-of-life treatment. a
Since 2019, AstraZeneca's Scope 3 emissions have remained relatively stable, indicating that AstraZeneca 's emissions have plateaued with no significant change in its value chain footprint. a
Compared to the previous year (2023), AstraZeneca's Scope 3 emissions remained relatively stable, indicating that AstraZeneca 's emissions have plateaued with no significant change in its value chain footprint. a
In 2024, AstraZeneca reported emissions for 12 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to AstraZeneca's Scope 3 emissions were: a
In 2024, AstraZeneca reported Scope 1 greenhouse gas (GHG) emissions of 125,386 tCO₂e and total revenues of USD 39,894 millions. This translates into an emissions intensity of 3.14 tCO₂e per millions USD. a
In 2024, AstraZeneca reported a Scope 1 emissions intensity of 3.14 tCO₂e per millions USD. Compared to the peer group median of 5.85 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a
In 2024, AstraZeneca ranked 4 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
This places AstraZeneca among the top performers, with one of the lowest emissions intensities relative to peers. a
In 2024, AstraZeneca reported a total carbon footprint of 6,240,234 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 0.66% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output. a
The largest contributor to AstraZeneca's total carbon footprint was Scope 3 emissions, accounting for 94.51% of the company's total carbon footprint, followed by Scope 2 emissions at 3.48%. a